Brian Skorney
Stock Analyst at Baird
(3.38)
# 957
Out of 4,944 analysts
115
Total ratings
44.44%
Success rate
5.22%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $13.47 | +286.04% | 4 | Aug 12, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $30 → $35 | $18.80 | +86.17% | 12 | Jul 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $83.36 | +45.15% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $11.64 | +175.03% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $128.93 | +97.78% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $556.56 | +5.47% | 15 | Apr 30, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $64.72 | -15.02% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $120.02 | -16.68% | 3 | Feb 12, 2025 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $12.39 | +142.13% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.44 | +1,036.36% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $6.85 | +191.97% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.46 | +460.54% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $3.18 | +214.47% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $284.98 | -24.56% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $128.89 | +39.65% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $4.67 | +499.57% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $28.48 | +117.70% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.10 | +381.48% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $35.99 | +75.05% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $387.77 | -16.19% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $15.20 | -34.21% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.86 | +9,340.56% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.39 | +76.99% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.65 | +18,081.82% | 3 | May 7, 2018 |
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $13.47
Upside: +286.04%
Sarepta Therapeutics
Jul 17, 2025
Maintains: Outperform
Price Target: $30 → $35
Current: $18.80
Upside: +86.17%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $83.36
Upside: +45.15%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $11.64
Upside: +175.03%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $128.93
Upside: +97.78%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $556.56
Upside: +5.47%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $64.72
Upside: -15.02%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $120.02
Upside: -16.68%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $12.39
Upside: +142.13%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.44
Upside: +1,036.36%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $6.85
Upside: +191.97%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $4.46
Upside: +460.54%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $3.18
Upside: +214.47%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $284.98
Upside: -24.56%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $128.89
Upside: +39.65%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $4.67
Upside: +499.57%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $28.48
Upside: +117.70%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.10
Upside: +381.48%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $35.99
Upside: +75.05%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $387.77
Upside: -16.19%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $15.20
Upside: -34.21%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.86
Upside: +9,340.56%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.39
Upside: +76.99%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.65
Upside: +18,081.82%